Multi-center Clinical Study on Hemoperfusion of KHA80

Inclusion Criteria:

1. Age ≥18 years old, regardless of sex;

2. According to the 2012 KDIGO guidelines, it was diagnosed as CKD5 (EGFR ≦ 15ml/(min ˙ 1.73m2));

3. receive regular hemodialysis (including hemodialysis filtration) for 4 hours twice aweek for ≧3 months;

4. blood β 2-mg ≥ 30 mg/L and/or PTH ≥ 600 pg/mL and/or IL-6 ≥ 16.2 pg/mL;

5. Sign the informed consent form.

Exclusion Criteria:

1. Those who are known to have allergic reactions, contraindications or intolerance tothe materials of dialyzers and hemoperfutors;

2. Patients with severe bleeding tendency and active bleeding, or with definitecoagulation dysfunction, with a platelet count of < 60× 109/L;

3. Hemodialysis blood flow < 200 ml/min.

4. Kt/V<1.2；

5. Serum albumin < 30g/L;

6. Parathyroid resection within one year;

7. people with low blood pressure and severe cardiopulmonary insufficiency;

8. lactating or pregnant women or those who plan to be pregnant within one year;

9. infection, history of malignant tumor, active stage of rheumatic immune disease;

10. Patients whose life expectancy is less than one year;

11. Other clinical researchers are currently or recently (within 30 days);

12. According to the researcher's judgment, the patient has other unsuitable conditions.